Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT): A Morphologic and Molecular Study of 26 Cases Confirms Recurrent NCOA1-3 Rearrangement.
Adult
Aged
Estrogen Receptor alpha
/ genetics
Female
Gene Rearrangement
Humans
Middle Aged
Neoplasm Proteins
/ genetics
Neoplasm Recurrence, Local
Nuclear Receptor Coactivator 1
/ genetics
Nuclear Receptor Coactivator 2
/ genetics
Nuclear Receptor Coactivator 3
/ genetics
Oncogene Fusion
Sex Cord-Gonadal Stromal Tumors
/ genetics
Uterine Neoplasms
/ genetics
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
30
8
2019
medline:
8
5
2020
entrez:
30
8
2019
Statut:
ppublish
Résumé
Uterine tumor resembling ovarian sex cord tumor (UTROSCT) is a rare mesenchymal neoplasm, of uncertain biological potential, that was recently reported to exhibit recurrent gene fusions involving NCOA2-3. The purpose of this study was to, using a larger sample size, better characterize the histopathologic and molecular diversity of UTROSCT. Twenty-six cases of UTROSCT from 5 institutions were selected for further study. Fluorescence in situ hybridization for NCOA1, NCOA2, NCOA3, ESR1 and GREB1, and targeted RNA sequencing was performed on 17 and 8 UTROSCTs, respectively. Eight cases underwent massively parallel sequencing to detect single nucleotide variants (SNV), copy number variations, and structural variants using a targeted hybrid-capture based assay. NCOA1-3 rearrangement was identified in 81.8% (18/22) of cases. The most common fusion was ESR1-NCOA3, occurring in 40.9% (9/22). GREB1-NCOA1 (n=4), ESR1-NCOA2 (n=3), and GREB1-NCOA2 (n=1) rearrangements were also identified. No recurrent SNVs were identified and no tumor had SNVs in FOXL2, DICER1, STK11, or AKT1, which can be seen in ovarian sex cord-stromal tumors. Copy number variations were infrequent. Clinical follow-up was available for 11 cases with a mean follow-up interval of 94.4 (range, 1 to 319) months. Only one case had a recurrence 66 months after the initial diagnosis and this was the single case with a GREB1-NCOA2 fusion. This study reports the morphologic spectrum of UTROSCT and confirms the recently reported recurrent NCOA2-3 gene fusions, in addition to identifying novel rearrangements involving NCOA1 in these tumors.
Identifiants
pubmed: 31464709
doi: 10.1097/PAS.0000000000001348
pii: 00000478-202001000-00004
pmc: PMC8223168
mid: NIHMS1535926
doi:
Substances chimiques
ESR1 protein, human
0
Estrogen Receptor alpha
0
GREB1 protein, human
0
NCOA2 protein, human
0
Neoplasm Proteins
0
Nuclear Receptor Coactivator 2
0
NCOA1 protein, human
EC 2.3.1.48
NCOA3 protein, human
EC 2.3.1.48
Nuclear Receptor Coactivator 1
EC 2.3.1.48
Nuclear Receptor Coactivator 3
EC 2.3.1.48
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
30-42Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA140146
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA217694
Pays : United States
Références
Ultrastruct Pathol. 2010 Feb;34(1):16-24
pubmed: 20070149
Expert Opin Ther Targets. 2014 Sep;18(9):1065-76
pubmed: 24998469
Oncogene. 2018 Nov;37(44):5873-5886
pubmed: 29973689
Arch Pathol Lab Med. 2008 Apr;132(4):595-605
pubmed: 18384211
Am J Surg Pathol. 2010 Dec;34(12):1749-61
pubmed: 21084963
Int J Gynecol Pathol. 2016 Jul;35(4):301-8
pubmed: 26598979
Int J Clin Exp Pathol. 2014 Feb 15;7(3):1051-9
pubmed: 24696722
Am J Surg Pathol. 2019 Feb;43(2):178-186
pubmed: 30273195
Am J Surg Pathol. 2015 May;39(5):618-23
pubmed: 25581731
Arch Pathol Lab Med. 2017 Jun;141(6):751-758
pubmed: 28557599
Genes Chromosomes Cancer. 2012 May;51(5):510-20
pubmed: 22337624
Genes Chromosomes Cancer. 2013 Jun;52(6):538-50
pubmed: 23463663
Am J Clin Pathol. 1976 Sep;66(3):512-25
pubmed: 961630
Am J Pathol. 1945 Jan;21(1):53-61
pubmed: 19970803
Am J Surg Pathol. 2016 Feb;40(2):224-35
pubmed: 26501226
Adv Anat Pathol. 2010 Mar;17(2):122-9
pubmed: 20179434
J Mol Diagn. 2016 Jul;18(4):516-26
pubmed: 27154512
Am J Surg Pathol. 2005 Feb;29(2):157-66
pubmed: 15644772
Am J Surg Pathol. 2009 Aug;33(8):1206-12
pubmed: 19542872
Pathology. 2016 Aug;48(5):434-40
pubmed: 27311867
Virchows Arch. 2018 Nov;473(5):615-626
pubmed: 30109475
Oncol Rep. 2014 Jul;32(1):40-4
pubmed: 24839999
Eur J Obstet Gynecol Reprod Biol. 2014 Oct;181:163-70
pubmed: 25150955
J Pathol. 2016 Feb;238(3):381-8
pubmed: 26592504
Obstet Gynecol Sci. 2015 Sep;58(5):418-22
pubmed: 26430670
Diagn Mol Pathol. 2003 Sep;12(3):174-80
pubmed: 12960700
Semin Diagn Pathol. 1988 May;5(2):199-222
pubmed: 2840723
Biol Reprod. 2014 Nov;91(5):122
pubmed: 25297546
Genes Chromosomes Cancer. 2013 Mar;52(3):330-1
pubmed: 23225380
Am J Surg Pathol. 2019 Jul;43(7):928-942
pubmed: 31094921
Expert Rev Mol Diagn. 2017 Feb;17(2):189-194
pubmed: 28058850
JCI Insight. 2016 Nov 17;1(19):e87062
pubmed: 27882345
Gynecol Oncol Rep. 2017 Jan 11;19:53-56
pubmed: 28119954
Histopathology. 2015 Jul;67(1):1-19
pubmed: 25355621
Genes Chromosomes Cancer. 2018 Apr;57(4):176-181
pubmed: 29218853
Genes Chromosomes Cancer. 2019 Mar;58(3):155-163
pubmed: 30350331
Int J Gynecol Pathol. 2008 Apr;27(2):229-35
pubmed: 18317219
Histopathology. 2017 Nov;71(5):751-759
pubmed: 28656712
J Clin Pathol. 2007 Oct;60(10):1148-54
pubmed: 17182656
Blood. 1998 May 1;91(9):3127-33
pubmed: 9558366
Onco Targets Ther. 2019 Feb 07;12:1071-1074
pubmed: 30799936
Mod Pathol. 2016 Jan;29 Suppl 1:S92-103
pubmed: 26715176
Mod Pathol. 2006 Jan;19(1):17-24
pubmed: 16118629
Genes Chromosomes Cancer. 2012 Feb;51(2):127-39
pubmed: 22034177